Tuesday, May 1, 2018

02/21/2018Fusion IV Pharmaceuticals, Inc. dba Axia PharmaceuticalLos Angeles District OfficeCompounding Pharmacy/Adulterated Drug ProductsNot Issued *

Chinese API maker Yinghua hit with FDA warning letter

Chinese API maker Yinghua Biochemical and Pharmaceutical Co. was issued a warning letter by the FDA for data integrity issues and problems with its quality unit

FDA hits Mexican drugmaker Degasa with warning letter

The FDA issued a warning letter to Mexican finished-pharmaceutical manufacturer Degasa for issues including misbranding, failing to conduct adequate testing and problems with its water system.

HHS Inspector General Dan Levinson Shares the OIG’s Latest Perspectives [Podcast]

By Adam Turteltaub adam.turteltaub@corporatecompliance.org On April 16, 2018 Daniel R. Levinson, the Inspector General at the Department of Health and Human Services once again returned to the stage for the HCCA Compliance Institute.  As he has done so many times and so well, he provided the Institute attendees the latest in thinking from the Office […] 
Read on »